Mar Rodríguez-Girondo

Mar Rodríguez-Girondo

Auto-generated profile, based on publicly available information

Mar Rodríguez-Girondo

Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2018 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
MGMaría Gallardo-Gómez
María Gallardo-Gómez
SMSebastian Moran
Sebastian Moran
MCMaría Páez De La Cadena
María Páez De La Cadena
VMVicenta Martinez-Zorzano
Vicenta Martinez-Zorzano
FRFrancisco Javier Rodríguez-Berrocal
Francisco Javier Rodríguez-Berrocal
LCLoretta De Chiara
Loretta De Chiara
Colorectal cancer is the fourth cause of cancer-related deaths worldwide, though detection at early stages associates with good prognosis. Thus, there is a clear demand for novel non-invasive tests for the early detection of colorectal cancer and premalignant advanced adenomas, to be used in population-wide screening programs. Aberrant DNA methylation detected in liquid biopsies, such as serum circulating cell-free DNA (cfDNA), is a promising source of non-invasive biomarkers. This study aimed to assess the feasibility of using cfDNA pooled samples to identify potential serum methylation biomarkers for the detection of advanced colorectal neoplasia (colorectal cancer or advanced adenomas) using microarray-based technology. cfDNA was extracted from serum samples from 20 individuals with no colorectal findings, 20 patients with advanced adenomas, and 20 patients with colorectal cancer (stages I and II). Two pooled samples were prepared for each pathological group using equal amounts of cfDNA from 10 individuals, sex-, age-, and recruitment hospital-matched. We measured the methylation levels of 866,836 CpG positions across the genome using the MethylationEPIC array. Pooled serum cfDNA methylation data meets the quality requirements. The proportion of detected CpG in all pools (> 99% with detection p value < 0.01) exceeded Illumina Infinium methylation data quality metrics of the number of sites detected. The differential methylation analysis revealed 1384 CpG sites (5% false discovery rate) with at least 10% difference in the methylation level between no colorectal findings controls and advanced neoplasia, the majority of which were hypomethylated. Unsupervised clustering showed that cfDNA methylation patterns can distinguish advanced neoplasia from healthy controls, as well as separate tumor tissue from healthy mucosa in an independent dataset. We also observed that advanced adenomas and stage I/II colorectal cancer methylation profiles, grouped as advanced neoplasia, are largely homogenous and clustered close together. This preliminary study shows the viability of microarray-based methylation biomarker discovery using pooled serum cfDNA samples as an alternative approach to tissue specimens. Our strategy sets an open door for deciphering new non-invasive biomarkers not only for colorectal cancer detection, but also for other types of cancers.

12 August 2015 in Scientific Reports
Verified
Journal Article
Open access
OOOlalla Otero-Estévez
Olalla Otero-Estévez
LCLoretta De Chiara
Loretta De Chiara
MRMar Rodríguez-Girondo
Mar Rodríguez-Girondo
FRFrancisco Javier Rodríguez-Berrocal
Francisco Javier Rodríguez-Berrocal
Joaquin CubiellaJoaquin Cubiella
Joaquin Cubiella
VMVicenta Martinez-Zorzano
Vicenta Martinez-Zorzano
Matrix metalloproteinase-9 (MMP-9) is related to tumour development and progression in colorectal cancer (CRC) and its utility as biomarker has been suggested. The aim of our study was to measure serum MMP-9 in asymptomatic first-degree relatives of CRC patients and to analyse its diagnostic accuracy for the detection of advanced neoplasia (AN: advanced adenomas and CRC). Additionally, we compared its diagnostic capability with the most used non-invasive faecal immunochemical test (FIT). Serum MMP-9 was quantified by ELISA in 516 asymptomatic individuals that underwent a colonoscopy and a FIT. MMP-9 levels were significantly related to age and gender and therefore the concentration was corrected by these confounders. Corrected MMP-9 (cMMP-9) levels were higher in individuals with advanced adenomas (AA; p-value = 0.029) and AN (p-value = 0.056) compared to individuals with no neoplasia. Moreover, elevated cMMP-9 concentration was associated with more severe characteristics of adenomas (number of lesions, size and histology). Nevertheless, the diagnostic accuracy of cMMP-9 was considerably lower than that of FIT for identifying AA (22.64% vs. 47.17% sensitivity, 90% specificity) or AN (19.30% vs. 52.63% sensitivity, 90% specificity). According to our results, serum MMP-9 cannot be considered of utility for the diagnosis of AN in CRC family-risk population screening.

18 May 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SBSonia Blanco-Prieto
Sonia Blanco-Prieto
LILorena Vázquez Iglesias
Lorena Vázquez Iglesias
MRMar Rodríguez-Girondo
Mar Rodríguez-Girondo
LBLeticia Barcia-Castro
Leticia Barcia-Castro
AFAlberto Fernandez-Villar
Alberto Fernandez-Villar
MCMaría Páez De La Cadena
María Páez De La Cadena
Lung cancer is the most lethal neoplasia, and an early diagnosis is the best way for improving survival. Symptomatic patients attending Pulmonary Services could be diagnosed with lung cancer earlier if high-risk individuals are promptly separated from healthy individuals and patients with benign respiratory pathologies. We searched for a convenient non-invasive serum test to define which patients should have more immediate clinical tests. Six cancer-associated molecules (HB-EGF, EGF, EGFR, sCD26, VEGF, and Calprotectin) were investigated in this study. Markers were measured in serum by specific ELISAs, in an unselected population that included 72 lung cancer patients of different histological types and 56 control subjects (healthy individuals and patients with benign pulmonary pathologies). Boosted regression and random forests analysis were conducted for the selection of the best candidate biomarkers. A remarkable discriminatory capacity was observed for EGF, sCD26, and especially for Calprotectin, these three molecules constituting a marker panel boasting a sensitivity of 83% and specificity of 87%, resulting in an associated misclassification rate of 15%. Finally, an algorithm derived by logistic regression and a nomogram allowed generating classification scores in terms of the risk of a patient of suffering lung cancer. In conclusion, we propose a non-invasive test to identify patients at high-risk for lung cancer from a non-selected population attending a Pulmonary Service. The efficacy of this three-marker panel must be tested in a larger population for lung cancer.

3 April 2013 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
Bertrand NapoléonBertrand Napoléon
Bertrand Napoléon
MAM. Victoria Alvarez-Sanchez
M. Victoria Alvarez-Sanchez
PLPhilippe Leclercq
Philippe Leclercq
FMFrancois MION
Francois MION
JPJean Pialat
Jean Pialat
JSJean Yves Scoazec
Jean Yves Scoazec

Verified
Journal Article
Open access
PDF file
LCLoretta De Chiara
Loretta De Chiara
VLVirginia Leiro-Fernández
Virginia Leiro-Fernández
MRMar Rodríguez-Girondo
Mar Rodríguez-Girondo
DVDiana Valverde
Diana Valverde
MBMaribel Isabel Botana Botana-Rial
Maribel Isabel Botana Botana-Rial
AFAlberto Fernandez-Villar
Alberto Fernandez-Villar
Different methodological approaches are available to assess DNA methylation biomarkers. In this study, we evaluated two sodium bisulfite conversion-dependent methods, namely pyrosequencing and methylation-specific qPCR (MS-qPCR), with the aim of measuring the closeness of agreement of methylation values between these two methods and its effect when setting a cut-off. Methylation of tumor suppressor gene p16/INK4A was evaluated in 80 lung cancer patients from which cytological lymph node samples were obtained. Cluster analyses were used to establish methylated and unmethylated groups for each method. Agreement and concordance between pyrosequencing and MS-qPCR was evaluated with Pearson’s correlation, Bland–Altman, Cohen’s kappa index and ROC curve analyses. Based on these analyses, cut-offs were derived for MS-qPCR. An acceptable correlation (Pearson’s R2 = 0.738) was found between pyrosequencing (PYRmean) and MS-qPCR (NMP; normalized methylation percentage), providing similar clinical results when categorizing data as binary using cluster analysis. Compared to pyrosequencing, MS-qPCR tended to underestimate methylation for values between 0 and 15%, while for methylation >30% overestimation was observed. The estimated cut-off for MS-qPCR data based on cluster analysis, kappa-index agreement and ROC curve analysis were much lower than that derived from pyrosequencing. In conclusion, our results indicate that independently of the approach used for estimating the cut-off, the methylation percentage obtained through MS-qPCR is lower than that calculated for pyrosequencing. These differences in data and therefore in the cut-off should be examined when using methylation biomarkers in the clinical practice.

13 September 2012 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
MRMar Rodríguez‐Girondo
Mar Rodríguez‐Girondo
JUJacobo de Uña‐Álvarez
Jacobo de Uña‐Álvarez